A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection

Trial Profile

A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2017

At a glance

  • Drugs TG 1050 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Transgene
  • Most Recent Events

    • 17 Oct 2016 According to Transgene media release, First Patient Randomized in Multiple Dose Cohort and first data readout is expected in second half of 2017.
    • 26 Sep 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2019.
    • 05 Sep 2016 According to a Transgene media release, the company expects the first data readout in second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top